• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由APC基因的小鼠同源基因中的突变引起的多发性肠道肿瘤形成

Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.

作者信息

Su L K, Kinzler K W, Vogelstein B, Preisinger A C, Moser A R, Luongo C, Gould K A, Dove W F

机构信息

Molecular Genetics Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD 21231.

出版信息

Science. 1992 May 1;256(5057):668-70. doi: 10.1126/science.1350108.

DOI:10.1126/science.1350108
PMID:1350108
Abstract

Germ-line mutations of the APC gene are responsible for familial adenomatous polyposis (FAP), an autosomal dominantly inherited disease in humans. Patients with FAP develop multiple benign colorectal tumors. Recently, a mouse lineage that exhibits an autosomal dominantly inherited predisposition to multiple intestinal neoplasia (Min) was described. Linkage analysis showed that the murine homolog of the APC gene (mApc) was tightly linked to the Min locus. Sequence comparison of mApc between normal and Min-affected mice identified a nonsense mutation, which cosegregated with the Min phenotype. This mutation is analogous to those found in FAP kindreds and in sporadic colorectal cancers.

摘要

APC基因的种系突变是家族性腺瘤性息肉病(FAP)的病因,FAP是人类一种常染色体显性遗传疾病。FAP患者会出现多个良性结肠直肠肿瘤。最近,描述了一种小鼠品系,其表现出对多发性肠道肿瘤(Min)的常染色体显性遗传易感性。连锁分析表明,APC基因的小鼠同源物(mApc)与Min位点紧密连锁。对正常小鼠和患Min小鼠的mApc进行序列比较,发现了一个无义突变,该突变与Min表型共分离。此突变类似于在FAP家族和散发性结直肠癌中发现的突变。

相似文献

1
Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene.由APC基因的小鼠同源基因中的突变引起的多发性肠道肿瘤形成
Science. 1992 May 1;256(5057):668-70. doi: 10.1126/science.1350108.
2
Mutations of the APC (adenomatous polyposis coli) gene in FAP (familial polyposis coli) patients and in sporadic colorectal tumors.家族性腺瘤性息肉病(FAP)患者及散发性结直肠癌肿瘤中APC(腺瘤性息肉病 coli)基因的突变。
Tohoku J Exp Med. 1992 Oct;168(2):141-7. doi: 10.1620/tjem.168.141.
3
A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors.小鼠Apc基因中的靶向链终止突变导致多个肠道肿瘤。
Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8969-73. doi: 10.1073/pnas.91.19.8969.
4
The genetic background of familial adenomatous polyposis. Linkage analysis, the APC gene identification and mutation screening.家族性腺瘤性息肉病的遗传背景。连锁分析、APC基因鉴定及突变筛查。
Acta Gastroenterol Belg. 1995 Sep-Dec;58(5-6):433-51.
5
Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients.家族性腺瘤性息肉病(FAP)和结直肠癌患者5号染色体长臂21区基因的突变
Science. 1991 Aug 9;253(5020):665-9. doi: 10.1126/science.1651563.
6
The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia.分泌型磷脂酶A2基因是Mom1位点的一个候选基因,Mom1位点是ApcMin诱导的肠道肿瘤形成的主要修饰因子。
Cell. 1995 Jun 16;81(6):957-66. doi: 10.1016/0092-8674(95)90015-2.
7
Mutations of the adenomatous polyposis coli gene in familial polyposis coli patients and sporadic colorectal tumors.家族性腺瘤性息肉病患者及散发性结直肠癌肿瘤中腺瘤性息肉病 coli 基因的突变
Princess Takamatsu Symp. 1991;22:285-92.
8
Effect of targeting janus kinase 3 on the development of intestinal tumors in the adenomatous polyposis coli(min) mouse model of familial adenomatous polyposis.靶向 Janus 激酶 3 对家族性腺瘤性息肉病的腺瘤性息肉病 coli(min) 小鼠模型中肠道肿瘤发生发展的影响
Arzneimittelforschung. 2007;57(6):320-9. doi: 10.1055/s-0031-1296626.
9
Mutation analysis of the adenomatous polyposis coli (APC) gene in northwest Spanish patients with familial adenomatous polyposis (FAP) and sporadic colorectal cancer.西班牙西北部家族性腺瘤性息肉病(FAP)和散发性结直肠癌患者腺瘤性息肉病大肠杆菌(APC)基因的突变分析。
Hum Mutat. 2001 Oct;18(4):355. doi: 10.1002/humu.1198.
10
Reduction in alkaline sphingomyelinase in colorectal tumorigenesis is not related to the APC gene mutation.结直肠癌发生过程中碱性鞘磷脂酶的减少与APC基因突变无关。
Int J Colorectal Dis. 2003 Jul;18(4):309-13. doi: 10.1007/s00384-002-0471-y. Epub 2003 Mar 4.

引用本文的文献

1
Tcf4 regulates secretory cell fate decisions in the small intestine and colon tumors: insights from transcriptomic, histological, and microbiome analyses.Tcf4调控小肠和结肠肿瘤中的分泌细胞命运决定:来自转录组学、组织学和微生物组分析的见解
Stem Cell Res Ther. 2025 Apr 12;16(1):170. doi: 10.1186/s13287-025-04280-y.
2
Roux-en-Y gastric bypass-associated fecal tyramine promotes colon cancer risk via increased DNA damage, cell proliferation, and inflammation.Roux-en-Y胃旁路手术相关的粪便酪胺通过增加DNA损伤、细胞增殖和炎症反应来提高患结肠癌的风险。
Microbiome. 2025 Feb 28;13(1):60. doi: 10.1186/s40168-025-02049-2.
3
Multitarget mechanism of MYC inhibition by the bacterial lon protease in disease.
细菌Lon蛋白酶在疾病中抑制MYC的多靶点机制。
Sci Rep. 2025 Feb 25;15(1):6778. doi: 10.1038/s41598-025-88093-2.
4
Winnie Mice: A Chronic and Progressive Model of Ulcerative Colitis.温妮小鼠:一种溃疡性结肠炎的慢性进行性模型。
Inflamm Bowel Dis. 2025 Apr 10;31(4):1158-1167. doi: 10.1093/ibd/izaf006.
5
HMGA1 is a crucial mediator of colon tumorigenesis driven by the loss of APC.HMGA1是由APC缺失驱动的结肠肿瘤发生的关键介导因子。
J Clin Invest. 2025 Feb 3;135(3):e187442. doi: 10.1172/JCI187442.
6
HMGA1 acts as an epigenetic gatekeeper of ASCL2 and Wnt signaling during colon tumorigenesis.在结肠癌发生过程中,HMGA1作为ASCL2和Wnt信号通路的表观遗传守门人。
J Clin Invest. 2025 Feb 3;135(3):e184442. doi: 10.1172/JCI184442.
7
Crypt density and recruited enhancers underlie intestinal tumour initiation.隐窝密度和募集的增强子是肠道肿瘤起始的基础。
Nature. 2025 Apr;640(8057):231-239. doi: 10.1038/s41586-024-08573-9. Epub 2025 Jan 8.
8
METTL3-VISTA axis-based combination immunotherapy for APC truncation colorectal cancer.基于METTL3-VISTA轴的联合免疫疗法治疗APC截短型结直肠癌
J Immunother Cancer. 2024 Dec 9;12(12):e009865. doi: 10.1136/jitc-2024-009865.
9
Enhanced CRC Growth in Iron-Rich Environment, Facts and Speculations.富含铁环境下 CRC 生长增强,事实与推测。
Int J Mol Sci. 2024 Nov 19;25(22):12389. doi: 10.3390/ijms252212389.
10
Kallikrein-Related Peptidase 6 Contributes to Murine Intestinal Tumorigenesis Driven by a Mutant Gene.激肽释放酶相关肽酶6促进由突变基因驱动的小鼠肠道肿瘤发生。
Cancers (Basel). 2024 Nov 15;16(22):3842. doi: 10.3390/cancers16223842.